The FDA approval of Amgen’s interchangeable Stelara biosimilar is raising broader questions about how potential competition could impact Medicare price negotiations for Johnson & Johnson’s blockbuster.
Stelara (ustekinumab) was first approved in 2009 and last year generated nearly $6.4 billion in US sales in a slate of inflammatory conditions, according…
Click here to view original post
